Biomatter Raises $18M to Scale AI Enzyme Design
Lithuania-based Biomatter closed an oversubscribed $18 million Series A round led by agrifood investor Astanor to expand its AI-driven enzyme design platform. The funding will support a new 2,000 m² facility in Vilnius and commercial growth in the US, targeting applications in food and biomanufacturing.
Lithuania-based enzyme design company Biomatter has closed an oversubscribed $18 million Series A funding round. Brussels-based agrifood investor Astanor led the round, with participation from existing investors UVC Partners, Inventure and Metaplanet. Company Growth and New Facility The funding will go toward a new 2,000 square metre enzyme design and testing facility in Vilnius, which is due to open in 2027. According to Cultivated X and vegconomist.com, the financing will also support an expanded commercial presence in the US. TMCnet and Unite.AI add that roughly half of the company's customers are based in the United States, and the round will fund further development of the computational platform and its underlying enzyme dataset. Biomatter's current programs run in weeks, and the new facility is meant to cut that timeframe to days by bringing more laboratory building and testing in-house. Laurynas Karpus, CEO and co-founder of Biomatter, stated that the goal is to make a custom enzyme as easy to order as a catalog product, including for reactions that do not have one today. Oliver Schoppe, Partner at UVC Partners, noted that Biomatter's enzymes are already in products shipping from major manufacturers in Europe and the United States. Harry Briggs, Partner at Astanor, highlighted that enzymes power hundreds of billions of dollars in food production and biomanufacturing. AI Technology and Applications Founded in 2018, Biomatter uses AI and physics-based models to design enzymes starting from the chemical reaction a customer needs, rather than starting with natural enzymes and their data. The company tests each design in its own lab before shipment, adding to a proprietary dataset that grows with every program and makes subsequent work faster and more accurate. The founders published one of the first demonstrations that generative models can produce functional enzymes far from anything found in nature in Nature Machine Intelligence in 2021. Biomatter has delivered more than 50 custom enzymes to over 25 enterprise customers spanning biopharma, diagnostics, agriculture and industrial biotechnology. Named customers include AstraZeneca, BASF, Kirin Holdings, Neogen, Sanofi and Tereos. Business News Today is cited by Cultivated X and vegconomist.com as the source for the customer list. Several accounts have grown from a single project into multi-year, multi-enzyme programs. In food, Biomatter worked with Kirin on an enzyme-based process for producing human milk oligosaccharides, and in 2025 agreed to develop enzyme-based food safety products with Neogen. TMCnet and Unite.AI note that Biomatter's work includes a collaboration with Thermo Fisher Scientific on Invitrogen SuperScript V Reverse Transcriptase, an enzyme used to convert RNA into DNA, which improved oxidation resistance for ambient shipping and room-temperature storage for up to six months. Biomatter also created a methylase enzyme for mRNA vaccine manufacturing that works without SAM, an expensive additive required by every natural methylase. Cultivated X and vegconomist.com also note that Amsterdam and Zurich-based Cradle raised $73 million in 2024 for a platform with applications including animal-free foods, Enzymit is developing designer enzymes for fermentation, and Pentasweet is building a €65 million precision fermentation plant for brazzein in Vilnius.
Read source: Cultivated X